Abstract
Hemolytic Uremic Syndrome (HUS) is an acute and potentially fatal condition, often triggered by Shiga toxin produced by Escherichia coli. Characterized by severe complications such as thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney failure, HUS is most commonly observed in children. A promising therapeutic approach to neutralize the adverse effects of Shiga toxin is …